Cerus Co. (NASDAQ:CERS) Director Sells $35,600.00 in Stock

Cerus Co. (NASDAQ:CERS) Director Eric Bjerkholt sold 20,000 shares of Cerus stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $1.78, for a total value of $35,600.00. Following the completion of the sale, the director now directly owns 162,133 shares in the company, valued at $288,596.74. This represents a 10.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Cerus Stock Up 5.3 %

Shares of NASDAQ CERS opened at $1.80 on Tuesday. The stock has a market capitalization of $334.29 million, a price-to-earnings ratio of -16.36 and a beta of 1.24. Cerus Co. has a 52 week low of $1.38 and a 52 week high of $2.59. The firm has a 50-day moving average price of $1.75 and a 200 day moving average price of $1.91. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus reduced their price target on Cerus from $6.00 to $3.00 and set a “buy” rating for the company in a report on Thursday, October 17th.

Institutional Investors Weigh In On Cerus

Hedge funds and other institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. raised its holdings in Cerus by 13.8% during the third quarter. Franklin Resources Inc. now owns 93,763 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 11,338 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Cerus by 1.6% in the third quarter. Geode Capital Management LLC now owns 4,415,453 shares of the biotechnology company’s stock valued at $7,685,000 after buying an additional 69,950 shares in the last quarter. Barclays PLC raised its stake in shares of Cerus by 16.2% during the 3rd quarter. Barclays PLC now owns 1,575,049 shares of the biotechnology company’s stock worth $2,740,000 after buying an additional 219,755 shares during the last quarter. XTX Topco Ltd boosted its position in shares of Cerus by 18.7% in the 3rd quarter. XTX Topco Ltd now owns 178,431 shares of the biotechnology company’s stock worth $310,000 after buying an additional 28,063 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Cerus by 2.2% in the 3rd quarter. State Street Corp now owns 3,738,893 shares of the biotechnology company’s stock worth $6,506,000 after buying an additional 79,505 shares in the last quarter. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.